Stay updated on Durvalumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Durvalumab Combo in Resectable NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe government funding operating status notice was removed from the page. The rest of the study history and related content remains unchanged.SummaryDifference0.5%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA new version entry (23) was added to the record history on 2022-02-23. It updates the Study Status and related documentation.SummaryDifference0.1%

- Check48 days agoChange DetectedUpdated operating status notice and version to v3.2.0; removes previous v3.1.0 reference and directs users to current status sources.SummaryDifference11%

- Check55 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new release version.SummaryDifference0.3%

- Check69 days agoChange DetectedVersion updated to v3.0.2 (replacing v3.0.1) and the Back to Top element has been removed.SummaryDifference0.6%

- Check77 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.6%

Stay in the know with updates to Durvalumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.